TELA Bio publishes 24-month BRAVO study showing 2.6% recurrence rate with OviTex in hernia repair

TELA Bio, Inc.

BRAVO study 24-month analysis published in Annals of Medicine and Surgery; 92 patients enrolled.
OviTex 1S Permanent demonstrated a 2.6% hernia recurrence rate at 24 months via open, laparoscopic, or robotic techniques.
Patient quality-of-life showed statistically significant improvement from baseline at 3, 12, and 24 months.
Surgical site occurrences in 38% of patients; 78% were high-risk (obesity, smoking, COPD, diabetes, etc.).
CEO states commitment to ongoing BRAVO II study evaluating OviTex in robot-assisted repairs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.